<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785146</url>
  </required_header>
  <id_info>
    <org_study_id>zsly Huaier-1</org_study_id>
    <nct_id>NCT02785146</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer</brief_title>
  <official_title>Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qidong Gaitianli Medicines Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, paralleled control clinical study investigating Huaier Granule for prevention
      of recurrence and metastasis of colorectal cancer after radical surgery, to evaluate the
      efficacy and safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>1 year</time_frame>
    <description>DFS was defined as the date of definitive surgery until the date of recurrence, metastasis, appearance of a second primary tumor, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>OS was defined as the date of definitive surgery until the date of death or the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>5 years</time_frame>
    <description>RFS was defined as the date of definitive surgery until the date of recurrence or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival (MFS)</measure>
    <time_frame>5 years</time_frame>
    <description>MFS was defined as the date of definitive surgery until the date of metastasis or death from any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The effects of Huaier Granule on adverse events of adjuvant chemotherapy.</measure>
    <time_frame>6 months</time_frame>
    <description>The adverse events were evaluated every 2 weeks; Eastern Cooperative Oncology Group(ECOG) scores, imaging assessment and related biochemical indicators.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>mFOLFOX6 + Huaier Granule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ). Huaier Granule will be administrated from the first cycle of chemotherapy until 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaier Granule</intervention_name>
    <description>Huaier Granule is continuously taken three times per day, 20g per time.</description>
    <arm_group_label>mFOLFOX6 + Huaier Granule</arm_group_label>
    <other_name>Huaier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m², ivdrip, D1</description>
    <arm_group_label>mFOLFOX6 + Huaier Granule</arm_group_label>
    <arm_group_label>mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium folinate</intervention_name>
    <description>Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1</description>
    <arm_group_label>mFOLFOX6 + Huaier Granule</arm_group_label>
    <arm_group_label>mFOLFOX6</arm_group_label>
    <other_name>Calcium levofolinate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>400 mg/m², iv, D1; and 2400mg/m², civ, 48h</description>
    <arm_group_label>mFOLFOX6 + Huaier Granule</arm_group_label>
    <arm_group_label>mFOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects volunteer to sign the informed consent

          -  Aged: 18 to 75 years old

          -  Colorectal cancer (AJCC-TNM, high-risk Stage II and Stage III)

          -  The diagnosis and colorectal cancer has been confirmed by pathological examination
             after radical surgery

          -  The liver and kidney function satisfies the following conditions within 15 days after
             surgery (excluding day 15): aspartate aminotransferase (AST), glutamic-oxalacetic
             transaminase (ALT), alkaline phosphatase (ALP)&lt; 2 upper limit of normal (ULN), total
             bilirubin ≤ 1.5 ULN, serum creatinine &lt; 1.5 ULN; normal coagulation function

          -  Other laboratory tests meet the following requirements within 15 days after surgery
             (excluding day 15): white blood cells count ≥ 3.0×109/L, absolute neutrophil count ≥
             1.5×109/L, platelet count ≥ 100×109/L

          -  ECOG：0-2 points

          -  No other previous history of malignancy.

        Exclusion Criteria:

          -  Multiple primary cancer

          -  Not recover from the colorectal surgery

          -  Presence of organ, bone, or skin metastases

          -  Pregnant or lactating women

          -  Those with active bleeding due to various reasons

          -  Those with HIV infection or AIDS-associated diseases

          -  Those with severe acute and chronic diseases

          -  Those with severe diabetes

          -  Those with serious infectious diseases

          -  Those who can not take drugs by oral route

          -  Drug abusers or those with psychological or mental diseases that may interfere with
             study compliance

          -  Conditions that are considered not suitable for this study investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojian Wu, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaojian Wu, Ph.D.</last_name>
    <phone>+86-13760608396</phone>
    <email>wuxjian@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sixth Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojian Wu, Ph.D.</last_name>
      <phone>+86-13760608396</phone>
      <email>wuxjian@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zhang N, Kong X, Yan S, Yuan C, Yang Q. Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci. 2010 Nov;101(11):2375-83. doi: 10.1111/j.1349-7006.2010.01680.x.</citation>
    <PMID>20718753</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Zhang N, Huo Q, Yang Q. Anti-angiogenic and antitumor activities of Huaier aqueous extract. Oncol Rep. 2012 Oct;28(4):1167-75. doi: 10.3892/or.2012.1961. Epub 2012 Aug 8.</citation>
    <PMID>22895629</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang T, Wang K, Zhang J, Wang X, Chen Z, Ni C, Qiu F, Huang J. Huaier aqueous extract inhibits colorectal cancer stem cell growth partially via downregulation of the Wnt/β-catenin pathway. Oncol Lett. 2013 Apr;5(4):1171-1176. Epub 2013 Jan 21.</citation>
    <PMID>23599758</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Zhang N, Huo Q, Sun M, Dong L, Zhang Y, Xu G, Yang Q. Huaier aqueous extract inhibits stem-like characteristics of MCF7 breast cancer cells via inactivation of hedgehog pathway. Tumour Biol. 2014 Nov;35(11):10805-13. doi: 10.1007/s13277-014-2390-2. Epub 2014 Jul 31.</citation>
    <PMID>25077927</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>June 7, 2016</last_update_submitted>
  <last_update_submitted_qc>June 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiaojian Wu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Huaier Granule</keyword>
  <keyword>After radical surgery</keyword>
  <keyword>Prevention of recurrence and metastasis</keyword>
  <keyword>Efficacy and safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators would like to share the data to the Participating units.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

